Company Overview and News

4
Bertam Alliance says still working on regularisation plan

2018-07-02 theedgemarkets
KUALA LUMPUR (July 2): Bertam Alliance Bhd, a Practice Note 17 (PN17) company, said it is still working towards a plan to regularise its financial condition.
9814 BSMAF 1818

4
Trading of Bertam Alliance shares suspended from Thursday

2018-05-08 thestar.com.my
The trading suspension was triggered after Bertam missed the April 30 deadline to submit its annual report that includes the annual audited financial statements together with the auditors’ and directors’ reports for the financial year ended Dec 31, 2017.
9814 BSMAF 1818

4
Bertam Alliance tumbles after triggering PN17

2018-04-05 thestar.com.my
KUALA LUMPUR: Shares of Bertam Alliance Bhd fell sharply on Thursday after company triggered the Practice Note 17 (PN17).
9814 BSMAF 1818

4
Trading ideas: Seacera, Bertam Alliance, Hiap Teck

2018-04-05 thestar.com.my
KUALA LUMPUR: JF Apex Research expects Seacera Group Bhd , Bertam Alliance Bhd and Hiap Teck Venture Bhd to be among the stocks to watch on Thursday.
7073 5072 9814 BSMAF 1818

Related Articles

CATB: Catabasis Pharmaceuticals Analysis and Research Report

2018-07-13 - Asif

Overview Catabasis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics based on its proprietary Safely Metabolized And Rationally Targeted linker, or SMART LinkerSM, drug discovery platform. The company's SMART Linker drug discovery platform enables it to engineer product candidates that can simultaneously modulate multiple targets in a disease. The company's proprietary product candidates impact pathways that are central to diseases where efficacy may be optimized by a multiple target approach. Catabasis Pharmaceuticals has applied its SMART Linker drug discovery platform to build an internal pipeline of product candidates for rare diseases, its primary focus, and plan to pursue partnerships to develop additional product candidates. The company's lead product candidate is edasalonexent, formerly known as CAT-1004, which the company believe has the potential to be a disease-modifying...

WMT: Walmart Analysis and Research Report

2018-07-09 - Asif

Overview Walmart Inc. helps people around the world save money and live better – anytime and anywhere – in retail stores and through eCommerce. Through innovation, Walmart is striving to create a customer-centric experience that seamlessly integrates its eCommerce and retail stores in an omni-channel offering that saves time for its customers. Each week, the company serve nearly 270 million customers who visit its more than 11,700 stores and numerous eCommerce websites under 65 banners in 28 countries. The company's strategy is to lead on price, invest to differentiate on access, be competitive on assortment and deliver a great experience. Leading on price is designed to earn the trust of its customers every day by providing a broad assortment of quality merchandise and services at everyday low prices ("EDLP"). EDLP is its pricing philosophy under which the company price items at a low price every day so its customers trust that its prices will not change under frequent prom...

NVRO: Nevro Corp Analysis and Research Report

2018-07-06 - Asif

Overview Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from chronic pain. Nevro has developed and commercialized the Senza® spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain. The company's proprietary paresthesia-free HF10TM therapy, delivered by its Senza system, was demonstrated in its SENZA-RCT study to be superior to traditional SCS therapy with it being nearly twice as successful in treating back pain and 1.5 times as successful in treating leg pain when compared to traditional SCS therapy. Comparatively, traditional SCS therapy has limited efficacy in treating back pain and is used primarily for treating leg pain, limiting its market adoption. The company's SENZA-RCT study, along with its European studies, represents what the company believe is the most robust body of clinical evidence for any SCS therapy. The compa...